Habib Dable is a versatile, patient-focused executive with approximately 28 years in “Big Pharma” and “Emerging Biotech” environments, currently an Independent Director at Blueprint Medicines Corporation and part-time Venture Partner at RA Ventures. Most recently, Mr. Dable was President & CEO of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases until its sale to Merck in 2021 for $11.5B. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility, including President of U.S. Pharmaceuticals, Executive Vice President, Global Head Specialty Medicine. Mr. Dable led the launch of various blockbuster brands, including EYLEA^®, Stivarga^®, and Xofigo^®.  Mr. Dable is a previous member of the Board of Directors for BIO (Biotechnology Innovation Organization) and prior Independent Board Director for Millendo Therapeutics.

Mr. Dable holds a Master’s and Bachelor’s degree in business administration from the University of New Brunswick and completed an executive program from Stanford University’s Graduate School of Business.